Company profile for n-Lorem Foundation

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

n-Lorem’s mission is to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotides (ASO) medicines to treat patients with ultra-rare diseases (<10 patients).n-Lorem is focused on creating individual treatments for patients in the United States with ultra-rare diseases caused by genetic mutations that affect approximately n1-10 patients in the world....
n-Lorem’s mission is to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotides (ASO) medicines to treat patients with ultra-rare diseases (<10 patients).n-Lorem is focused on creating individual treatments for patients in the United States with ultra-rare diseases caused by genetic mutations that affect approximately n1-10 patients in the world. Diseases or conditions with broader patent populations are likely more suitable for treatment by other non-profit or for-profit entities, which we encourage you to explore with your physician.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2888 Loker Avenue East, Ste. 113 Carlsbad, CA 92010
Telephone
Telephone
(760) 552-7113
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251002216594/en/n-Lorem-Foundation-Organizes-Third-Annual-Nano-rare-Patient-Colloquium-Highlighting-Scientific-and-Clinical-Advancements-Achieved-Since-Organizations-Founding

BUSINESSWIRE
02 Oct 2025

https://www.businesswire.com/news/home/20250819544430/en/n-Lorem-Foundation-Publishes-Study-Showing-Targeted-ASO-Therapy-Restores-GBE1-Protein-in-APBD-Patient-Cells

BUSINESSWIRE
19 Aug 2025

https://www.businesswire.com/news/home/20250415314745/en/n-Lorem-Foundation-Celebrates-Five-Years-of-Bringing-Hope-and-Potential-Treatments-to-Nano-rare-Patients

BUSINESSWIRE
15 Apr 2025

https://www.businesswire.com/news/home/20241217534463/en/GondolaBio-and-n-Lorem-Foundation-Partner-to-Advance-Novel-ASO-Therapies-for-Genetic-Diseases

BUSINESSWIRE
17 Dec 2024

https://www.businesswire.com/news/home/20241217534463/en

BUSINESSWIRE
17 Dec 2024

https://www.businesswire.com/news/home/20241212041199/en

BUSINESSWIRE
12 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty